A Phase 3 interventional study of NNC0487-0111 and Semaglutide in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Active, not recruiting at 122 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.
Among the 24 studies testing zenagamtide in Obesity, this one is the 4th largest by enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 14 of the 19 other live ones, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 19 started in 2026.
This study's enrollment of 985 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 360 across the 24 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 24 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 14th largest by enrollment of the 166 interventional ones that give a count, is one of 47 that started in 2026, is one of 62 in phase 3, reaches primary completion later than 57 of the 65 other live ones, and was the 164th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing zenagamtide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator). Which treatment participants get is decided by chance.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive NNC0487-0111 and placebo matched to semaglutide subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: NNC0487-0111 · Drug: Placebo (matched to semaglutide)
Participants will receive semaglutide and placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity.
Drug: Semaglutide · Drug: Placebo (matched to NNC0487-0111)
NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Semaglutide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo matched to NNC0487-0111 will be administered subcutaneously using pre- filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Placebo matched to semaglutide will be administered subcutaneously using pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
Relative change in body weight
Measured as percentage of body weight.
Time frame: From baseline (week 0) to week 84
Change in waist circumference
Measured as centimeter (cm).
Time frame: From baseline (week 0) to week 84
Change in systolic blood pressure (SBP)
Measured as millimeter of mercury (mmHg).
Time frame: From baseline (week 0) to week 84
Change in body weight
Measured as kilograms (kg).
Time frame: From baseline (week 0) to week 84 and week 104
Change in body mass index (BMI)
Measured as kilograms per meter squared (kg/m\^2).
Time frame: From baseline (week 0) to week 84 and week 104
Number of participants with achievement of in haemoglobin A1c (HbA1c) < 7.0 percent (%) (yes/no)
Measured as count of participants.
Time frame: From baseline (week 0) to week 84
Number of participants with achievement of HbA1c ≤ 6.5% (yes/no)
Measured as count of participants.
Time frame: From baseline (week 0) to week 84
Number of participants with achievement of HbA1c < 5.7% (yes/no)
Measured as count of participants.
Time frame: From baseline (week 0) to week 84
Change in fasting plasma glucose (FPG) measured as millimole per liter (mmol/L)
Measured as mmol/L.
Time frame: From baseline (week 0) to week 84
Change in FPG measured as milligrams per deciliter (mg/dL)
Measured as mg/dL.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in fasting insulin
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in urinary albumin-to-creatinine ratio (UACR)
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Change in diastolic blood pressure (DBP)
Measured as mmHg.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in total cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in high-density lipoprotein (HDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in low-density lipoprotein (LDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in very low-density lipoprotein (VLDL) cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in non-HDL cholesterol
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in triglycerides
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Ratio to baseline: change in high-sensitivity C-reactive protein (hsCRP)
Measured as ratio.
Time frame: From baseline (week 0) to week 84
Number of Treatment Emergent Adverse Events (TEAEs)
Measured as events.
Time frame: From baseline (week 0) to week 84 and week 109
Number of Treatment Emergent Serious Adverse Events (TESAEs)
Measured as events.
Time frame: From baseline (week 0) to week 84 and week 109
Number of TEAEs leading to permanent treatment discontinuation
Measured as events.
Time frame: From baseline (week 0) to week 84 and week 109
Number of treatment-emergent clinically significant hypoglycaemic episodes (level 2) (< 3.0 millimole per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by a blood glucose (BG) meter)
Measured as episodes.
Time frame: From baseline (week 0) to week 84 and week 109
Number of treatment-emergent severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as episodes.
Time frame: From baseline (week 0) to week 84 and week 109
Showing the first 100 of 122 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 30 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Completion moved once since we started tracking on Sep 25, 2026: Jan 2029 → Dec 2028, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zenagamtide